Answers are grounded in this paper and cite their sources.
Plant-derived cosmetic ingredients sharing a botanical name can differ in plant parts, provenance, processing, native-extract contents, carriers, and intended uses. These differences affect composition, identity features, hazard profiles, analytical performance, and the transferability of evidence or finished-product limits. Authentication studies, phytochemical research, pharmacopoeias, safety guidance, and regulations address different parts of this problem. However, they provide no common procedure for translating heterogeneous evidence into an executable ingredient specification. This structured narrative review proposes a decision sequence that begins with the definition of the supplied ingredient and a decision-specific comparability domain. It then links each source of variation or harm to a critical attribute, analytical method, and evidence appraisal. The resulting output is an acceptance criterion, condition of use, or management measure. Numerical derivation stops when an essential material, analytical, or exposure bridge remains unresolved. Three cases examine Centella asiatica extract, expressed lemon peel oil, and pyrrolizidine-alkaloid contamination. They show how different evidence gaps lead to different outputs and data needs. The cases illustrate the framework but do not validate its performance or establish universal limits for plant-derived cosmetic ingredients.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: